Swiss Drug Firm Collaborates With Amgen to Develop Treatments for Alzheimer's Disease

Novartis and California-based biotech company Amgen will jointly develop neuroscience treatments for illnesses like Alzheimer's disease and migraine headaches.

Novartis partners with the California-based biotech company Amgen to develop and sell neuroscience treatments for illnesses and ailments like Alzheimer's disease and migraine headaches.//

Novartis stated, “Amgen will make initial payments and cover some research and development costs at the start with regard to the BACE inhibitor program for treatment of Alzheimer's. That will be followed by a 50-50 cost and profit sharing arrangement.”

Novartis Acquires Rights to GSK's Ofatumumab Drug For Multiple Sclerosis Treatment
The Swiss pharma will handle the worldwide development and commercialization of the drug - Ofatumumab - for use in multiple sclerosis, sources said.

As for migraine, Novartis will fund some R&D expenses for an agreed period and pay Amgen double-digit royalties on sales. The Basel-based company will also receive some commercialization and co-development rights to "the investigative molecules in Amgen's migraine portfolio."

Source-Medindia

Novartis' Oxytocin Nasal Spray can Help Men Reduce Calorie Intake
A new study has revealed that Novartis' oxytocin nasal spray, a synthetic nasal formulation of the love hormone, can help men eat fewer calories.

Young Blood to Cure Decline of Aging Brain
A research showed that injections of juvenile mouse blood boosts learning and memory in older rodents, findings that hold the long-sought cure for the decline of ageing brain.

Brain Protein Could be Targeted to Slow Alzheimer�s, Study Reveals
A protein that is involved in limiting flexibility in the aging brain could be targeted by new treatments which can slow the progression of Alzheimer’s disease.